Furthermore, by stratifying the analysis according to cancer stage (III/IV vs. I/II and I/II/III vs. IV), ITGB3 rs5918 significantly impacted OS among patients without distant metastases (I/II/III vs. IV; log-rank test, P = 0.021; Supplementary Figure S4a) but not among their counterparts (log-rank test, P = 0.147; Supplementary Figure S4b). Here, ITGB3 is linked to cancer.